Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC®, its proprietary implant for repairing damaged knee cartilage, in Israel. The announcement, detailed in a recent press release, marks a significant step in the company's commercialization strategy for its lead product.
GelrinC has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.
The agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate cartilage in a controlled and synchronous process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For investors, the deal provides a clear pathway to revenue in a new market and validates the company's regulatory and commercial strategy. The collaboration with AMI, a established player in the Israeli medical device market, could accelerate adoption and pave the way for reimbursement, which is critical for widespread access. The news comes as Regentis continues to advance its U.S. clinical program, potentially expanding its addressable market significantly upon approval.
To view the full press release, visit https://ibn.fm/t1dw4. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
MissionIR, a specialized communications platform, disseminated the announcement as part of its paid investor awareness and marketing engagement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services.
The agreement's impact extends beyond Regentis, highlighting the growing market for regenerative orthopedic solutions. With an aging population and increasing demand for minimally invasive treatments, GelrinC's off-the-shelf nature could offer a convenient alternative to current procedures. For the industry, the deal underscores the importance of strategic partnerships in navigating regulatory and reimbursement landscapes, especially for novel therapies. Patients in Israel with focal cartilage defects may soon have access to a new treatment option that could delay or prevent more invasive surgeries.
